REFERENCES
1. Hellings PW, Borrelli D, Pietikainen S, et al. European Summit on the
Prevention and Self-Management of Chronic Respiratory Diseases: report
of the European Union Parliament Summit (29 March 2017). Clin
Transl Allergy. 2017;7:49.
2. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic
vaccines for allergic diseases. A WHO position paper. J Allergy
Clin Immunol. 1998;102(4 Pt 1):558-562.
3. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S.
Allergen injection immunotherapy for seasonal allergic rhinitis.Cochrane Database Syst Rev. 2007(1):CD001936.
4. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice
parameter third update. J Allergy Clin Immunol. 2011;127(1
Suppl):S1-55.
5. Wise SK, Schlosser RJ. Subcutaneous and sublingual immunotherapy for
allergic rhinitis: what is the evidence? Am J Rhinol Allergy.2012;26(1):18-22.
6. Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration
as a novel method of allergen-specific immunotherapy. J Allergy
Clin Immunol. 2009;124(5):997-1002.
7. Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific
immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A
double-blind, placebo-controlled dose escalation study. J Allergy
Clin Immunol. 2012;129(1):128-135.
8. Jutel M, Akdis CA. Novel immunotherapy vaccine development.Curr Opin Allergy Clin Immunol. 2014;14(6):557-563.
9. Kundig TM, Johansen P, Bachmann MF, Cardell LO, Senti G.
Intralymphatic immunotherapy: time interval between injections is
essential. J Allergy Clin Immunol. 2014;133(3):930-931.
10. Soyka MB, van de Veen W, Holzmann D, Akdis M, Akdis CA. Scientific
foundations of allergen-specific immunotherapy for allergic disease.Chest. 2014;146(5):1347-1357.
11. Kundig TM, Klimek L, Schendzielorz P, Renner WA, Senti G, Bachmann
MF. Is The Allergen Really Needed in Allergy Immunotherapy? Curr
Treat Options Allergy. 2015;2(1):72-82.
12. Bachmann MF, Kundig TM. Allergen-specific immunotherapy: is it
vaccination against toxins after all? Allergy. 2017;72(1):13-23.
13. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson
HS. Sublingual immunotherapy: a comprehensive review. J Allergy
Clin Immunol. 2006;117(5):1021-1035.
14. Kariyawasam HK, Rotiroti G, Robinson DS. Sublingual immunotherapy in
allergic rhinitis: indications, efficacy and safety. Rhinology.2013;51(1):9-17.
15. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy
of grass-pollen immunotherapy. N Engl J Med. 1999;341(7):468-475.
16. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention
of new sensitizations in asthmatic children monosensitized to house dust
mite by specific immunotherapy. A six-year follow-up study. Clin
Exp Allergy. 2001;31(9):1392-1397.
17. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal
grass pollen immunotherapy in children. Allergy.2002;57(4):306-312.
18. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy
reduces the development of asthma in children with seasonal
rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol.2002;109(2):251-256.
19. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy
has long-term preventive effect of seasonal and perennial asthma:
10-year follow-up on the PAT study. Allergy. 2007;62(8):943-948.
20. Basomba A, Tabar AI, de Rojas DH, et al. Allergen vaccination with a
liposome-encapsulated extract of Dermatophagoides pteronyssinus: a
randomized, double-blind, placebo-controlled trial in asthmatic
patients. J Allergy Clin Immunol. 2002;109(6):943-948.
21. Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of
asthma and allergic disease. Adv Drug Deliv Rev.2009;61(3):256-262.
22. Senti G, Johansen P, Haug S, et al. Use of A-type CpG
oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy
in humans: a phase I/IIa clinical trial. Clin Exp Allergy.2009;39(4):562-570.
23. Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical
efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis:
a phase IIb study. Clin Exp Allergy. 2011;41(9):1305-1312.
24. Leuthard DS, Duda A, Freiberger SN, et al. Microcrystalline Tyrosine
and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect
from IgE-Mediated Reactivity in Mouse Models and Act Independently of
Inflammasome and TLR Signaling. J Immunol. 2018;200(9):3151-3159.
25. Zubeldia JM, Ferrer M, Davila I, Justicia JL. Adjuvants in
Allergen-Specific Immunotherapy: Modulating and Enhancing the Immune
Response. J Investig Allergol Clin Immunol. 2019;29(2):103-111.
26. Kundig TM, Senti G, Schnetzler G, et al. Der p 1 peptide on
virus-like particles is safe and highly immunogenic in healthy adults.J Allergy Clin Immunol. 2006;117(6):1470-1476.
27. Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary
clinical evaluation of a peptide immunotherapy vaccine for cat allergy.J Allergy Clin Immunol. 2011;127(1):89-97, 97 e81-14.
28. Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen
desensitization shows a persistent treatment effect 1 year after the
start of dosing: a randomized, placebo-controlled study. J Allergy
Clin Immunol. 2013;131(1):103-109 e101-107.
29. Focke-Tejkl M, Weber M, Niespodziana K, et al. Development and
characterization of a recombinant, hypoallergenic, peptide-based vaccine
for grass pollen allergy. J Allergy Clin Immunol.2015;135(5):1207-1207 e1201-1211.
30. Schmitz N, Dietmeier K, Bauer M, et al. Displaying Fel d1 on
virus-like particles prevents reactogenicity despite greatly enhanced
immunogenicity: a novel therapy for cat allergy. J Exp Med.2009;206(9):1941-1955.
31. Engeroff P, Caviezel F, Storni F, Thoms F, Vogel M, Bachmann MF.
Allergens displayed on virus-like particles are highly immunogenic but
fail to activate human mast cells. Allergy. 2018;73(2):341-349.
32. Shamji MH, Valenta R, Jardetzky T, et al. The role of
allergen-specific IgE, IgG and IgA in allergic disease. Allergy.2021.
33. Celebi Sozener Z, Mungan D, Cevhertas L, Ogulur I, Akdis M, Akdis C.
Tolerance mechanisms in allergen immunotherapy. Curr Opin Allergy
Clin Immunol. 2020;20(6):591-601.
34. Orengo JM, Radin AR, Kamat V, et al. Treating cat allergy with
monoclonal IgG antibodies that bind allergen and prevent IgE engagement.Nat Commun. 2018;9(1):1421.
35. Nakagome K, Nagata M. Allergen Immunotherapy in Asthma.Pathogens. 2021;10(11).
36. Bachmann MF, Mohsen MO, Kramer MF, Heath MD. Vaccination against
Allergy: A Paradigm Shift? Trends Mol Med. 2020;26(4):357-368.
37. Zha L, Leoratti FMS, He L, et al. An unexpected protective role of
low-affinity allergen-specific IgG through the inhibitory receptor
FcgammaRIIb. J Allergy Clin Immunol. 2018;142(5):1529-1536 e1526.
38. Thoms F, Jennings GT, Maudrich M, et al. Immunization of cats to
induce neutralizing antibodies against Fel d 1, the major feline
allergen in human subjects. J Allergy Clin Immunol.2019;144(1):193-203.
39. Beerli RR, Bauer M, Buser RB, et al. Isolation of human monoclonal
antibodies by mammalian cell display. Proc Natl Acad Sci U S A.2008;105(38):14336-14341.
40. Uermosi C, Beerli RR, Bauer M, et al. Mechanisms of
allergen-specific desensitization. J Allergy Clin Immunol.2010;126(2):375-383.
41. Uermosi C, Zabel F, Manolova V, et al. IgG-mediated down-regulation
of IgE bound to mast cells: a potential novel mechanism of
allergen-specific desensitization. Allergy. 2014;69(3):338-347.
42. Petersen RL. Strategies Using Bio-Layer Interferometry Biosensor
Technology for Vaccine Research and Development. Biosensors
(Basel). 2017;7(4).
43. Ngkelo A, Richart A, Kirk JA, et al. Mast cells regulate myofilament
calcium sensitization and heart function after myocardial infarction.J Exp Med. 2016;213(7):1353-1374.
44. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and
eosinophils. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S73-80.
45. Cildir G, Pant H, Lopez AF, Tergaonkar V. The transcriptional
program, functional heterogeneity, and clinical targeting of mast cells.J Exp Med. 2017;214(9):2491-2506.
46. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy.J Allergy Clin Immunol. 2007;119(4):780-791.
47. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited.Curr Opin Allergy Clin Immunol. 2004;4(4):313-318.
48. Nittner-Marszalska M, Malolepszy J, Zak-Nejmark T. [Skin tests,
total IgE and venom specific IgE and IgG4 in serum of bee-keepers].Pneumonol Alergol Pol. 1993;61(7-8):342-345.
49. Varga EM, Kausar F, Aberer W, et al. Tolerant beekeepers display
venom-specific functional IgG4 antibodies in the absence of specific
IgE. J Allergy Clin Immunol. 2013;131(5):1419-1421.
50. Engeroff P, Caviezel F, Storni F, Thoms F, Vogel M, Bachmann MF.
Allergens displayed on virus-like particles are highly immunogenic but
fail to activate human mast cells. Allergy. 2017.
Table 1: Kinetic parameters for the IgG1/IgG4 – CD32b
interaction calculated by BLI